Swk Hldgs Corp Stock Price, News & Analysis

SWK Holdings Corporation (Nasdaq: SWKH) announced on April 5, 2021, that its Special Committee received a non-binding proposal from Carlson Capital, L.P. to acquire its loan and royalty assets for $193 million in cash. The proposal includes a special dividend to stockholders post-acquisition. The Special Committee, composed of independent directors, will review the proposal with financial and legal advisors, ensuring the best interests of stockholders are prioritized. There is no guarantee that a definitive agreement will be reached regarding the acquisition.

SWK Holdings Corporation (SWKH) reported strong financial results for Q4 2020, with total revenue of $10.9 million, up 16% from $9.4 million in Q4 2019. Income producing assets peaked at $206 million, a 17.6% annual increase. The company closed a $9 million loan with Sincerus Pharmaceuticals in March 2021. Key metrics include an 11.9% adjusted return on tangible financing book value and a tangible book value per share of $15.84, reflecting a 7.5% rise year-over-year. SWK anticipates receiving additional milestone payments from Cara Therapeutics related to its Oral KORSUVA program under development.

Sincerus Pharmaceuticals has secured its largest investment to date from SWK Holdings Corporation (Nasdaq: SWKH) to support the expansion of a state-of-the-art customized medication manufacturing facility in the U.S. This funding aims to enhance Sincerus' capabilities in providing customized prescription medications for dermatologists, enabling better patient care without third-party payor constraints. Sincerus reported significant growth in 2020, driven by the introduction of new services. The investment is expected to further the development of dermatologic products, benefitting both patients and healthcare providers.

Enteris BioPharma, a subsidiary of SWK Holdings Corporation (SWKH), announced that Dr. Gary Shangold will host a webinar on the 505(b)(2) regulatory pathway on March 30, 2021, at 1:00 p.m. ET. The session will cover how this pathway can streamline drug development, enabling the introduction of innovative products. CEO Rajiv Khosla emphasized its potential to enhance the market value of new drugs. Attendees can register for the webinar via the provided link.

SWK Holdings Corporation (Nasdaq: SWKH) announced that Chairman and CEO Winston Black will present at the Maxim Group Emerging Growth Virtual Conference from March 17 to March 19, 2021. The presentation, which will be available on demand, will cover SWK's business strategy, recent corporate achievements, and future milestones. Additionally, Black will participate in a live 'fireside chat' on March 19 at 12 PM ET and hold virtual meetings with investors. The webcast will be accessible on the SWK investor relations website post-conference.

SWK Holdings Corporation (Nasdaq: SWKH) reported a 20% year-over-year increase in earning assets, reaching approximately $208 million, alongside a $35 million capital deployment in royalty transactions and loans. The company highlighted advancements in its subsidiary, Enteris BioPharma, including the completion of a manufacturing facility and collaboration with Cara Therapeutics on the Oral KORSUVA clinical program, which is now involved in four trials. Enteris received $3 million from Cara in milestone payments, with expectations for further payments based on development milestones.

Enteris BioPharma, a subsidiary of SWK Holdings (Nasdaq: SWKH), announced a webinar on January 19, 2021, titled "Strategies for Entering Phase 1 Clinical Development with Limited API Quantities." Co-hosted by Thomas Daggs and Angelo Consalvo, the webinar will focus on CMC strategies for pharmaceutical companies managing limited access to active pharmaceutical ingredients (API). CEO Rajiv Khosla highlighted the challenges faced by emerging biotech firms in drug development.

Enteris is advancing various clinical products, including Ovarest® and Tobrate™.

Enteris BioPharma has announced key developments in a recent press release, including the appointment of Rajiv Khosla as CEO and Gary A. Shangold as CMO. The company received $5 million in milestone payments from Cara Therapeutics for advancing Oral KORSUVA. Expansion of their manufacturing facility is on schedule, enabling Phase 3 production. Enteris aims for growth in 2021 by leveraging its Peptelligence and ProPerma delivery technologies and pursuing new partnerships. This positions the company for development opportunities in oral delivery solutions.

Flowonix Medical and SWK Holdings have successfully closed a financing deal worth approximately $33 million. This financing includes a $10 million debt facility from SWK and a $23 million Series B round led by Farallon Capital Management. The funds will support Flowonix's expansion in the chronic pain and spasticity markets, including product development and production line enhancements. The company anticipates improved performance in 2021, building on its resilience during 2020.